Suggested Dosing
Diabetes
200-400 mg standardized extract PO qDay-BID
Use only with regular blood glucose level monitoring
Suggested Uses
Diabetes mellitus, type 1 and 2
Constipation, digestive stimulant, diuresis, lipid lowering
Efficacy
Decr blood glucose & HgbA1C in type 1 or 2 DM
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (0)
Monitor Closely (0)
Minor (33)
- acarbose
gymnema increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.
- carbonyl iron
gymnema decreases levels of carbonyl iron by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- chlorpropamide
gymnema increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown.
- ferric maltol
gymnema decreases levels of ferric maltol by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- ferrous fumarate
gymnema decreases levels of ferrous fumarate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- ferrous gluconate
gymnema decreases levels of ferrous gluconate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- ferrous sulfate
gymnema decreases levels of ferrous sulfate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- glimepiride
gymnema increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.
- glipizide
gymnema increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.
- glyburide
gymnema increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin aspart
gymnema increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin detemir
gymnema increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin glargine
gymnema increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin glulisine
gymnema increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin lispro
gymnema increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin NPH
gymnema increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin regular human
gymnema increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.
- iron dextran complex
gymnema decreases levels of iron dextran complex by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- iron sucrose
gymnema decreases levels of iron sucrose by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- metformin
gymnema increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown.
- miglitol
gymnema increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown.
- nateglinide
gymnema increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown.
- pioglitazone
gymnema increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown.
- polysaccharide iron
gymnema decreases levels of polysaccharide iron by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- repaglinide
gymnema increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown.
- rose hips
gymnema decreases levels of rose hips by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- rosiglitazone
gymnema increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown.
- saxagliptin
gymnema increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown.
- shark cartilage
shark cartilage increases effects of gymnema by pharmacodynamic synergism. Minor/Significance Unknown. Enhanced blood sugar lowering effects (theoretical interaction).
- sitagliptin
gymnema increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown.
- tolazamide
gymnema increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.
- tolbutamide
gymnema increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown.
- vildagliptin
gymnema increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown.
Adverse Effects
Frequency Not Defined
None reported
Warnings
Contraindications
Hypersensitivity
Pregnancy
Pregnancy & Lactation
Pregnancy Category: X
Lactation: N/A
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Metabolism: N/A
Excretion: N/A
Mechanism of Action
Decrease intestinal absorption of glucose; may stimulate pancreatic beta cell growth
Incr serum C-peptide levels
